Cinclus Pharma

Cinclus Pharma abstract selected Poster of Excellence at the UEGW conference

Mon, Oct 15, 2018 08:00 CET

The Basel, Switzerland-based biotech company Cinclus Pharma AG today announced that its abstract P1152 was selected Poster of Excellence at the upcoming United European Gastroenterology Week, which is the largest annual meeting in Europe focused on GI-related diseases. The conference will be held in Vienna, Austria, October 20-24.The poster presentation will be given by Kjell Andersson, CEO at Cinclus Pharma AG, and Peter Unge, CMO at Cinclus Pharma AG, on October 23 at 12.30pm – 1.30pm.The title of Abstract P1152 is: THE NEW P-CAB X482 WAS SAFE, TOLERABLE AND PROVIDED 24H INTRAGASTRIC

First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD

Mon, Apr 16, 2018 10:30 CET

The Basel, Switzerland-based biotech company Cinclus Pharma AG today announced that it has successfully completed the first clinical Phase 1 study of its lead compound X842, for the treatment of severe erosive Gastroesophageal reflux disease (Erosive GERD Grade C and D).The study showed that X842 was safe and well tolerated. The strongly validated biomarker for healing of erosive GERD (eGERD), intragastric acidity, was possible to maintain above pH 4 for 24 hours after a single dose. Such acid control indicates that 100% healing rate of eGERD is achievable. The trial was an open label,

Share

Cinclus Pharma abstract selected Poster of Excellence at the UEGW conference

First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD